U.S. markets open in 2 hours 31 minutes
  • S&P Futures

    -6.50 (-0.19%)
  • Dow Futures

    -58.00 (-0.21%)
  • Nasdaq Futures

    -14.50 (-0.12%)
  • Russell 2000 Futures

    +1.60 (+0.10%)
  • Crude Oil

    +0.24 (+0.60%)
  • Gold

    -9.20 (-0.48%)
  • Silver

    -0.22 (-0.88%)

    -0.0031 (-0.26%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -0.03 (-0.10%)

    -0.0036 (-0.27%)

    +0.1310 (+0.13%)

    +1,916.07 (+17.33%)
  • CMC Crypto 200

    +16.05 (+6.55%)
  • FTSE 100

    -3.07 (-0.05%)
  • Nikkei 225

    -165.19 (-0.70%)

Coronavirus Latest: Monday, September 28

On Monday, Inovio announced that it would be halting its phase 2/3 coronavirus vaccine trial so that it could continue to answer questions from the FDA. This comes as the MidWest of the United States starts to see coronavirus positive cases topping 25%. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.

Video Transcript

MYLES UDLAND: Anjalee Khemlani joins us now for the latest on all of that. Anjalee, really some concerning figures here in the US, once again, particularly in the upper Midwest.

ANJALEE KHEMLANI: That's correct, Myles. We're starting to see positivity rates-- that means the tests that are coming back positive-- above 25%. And as we recall earlier in the pandemic, here in the Northeast, that was a very concerning number. So what we're looking at right now is really two different worlds. While one part of the US continues to battle, you know, the first wave, including those regions, North Dakota, South Dakota, we've also seen back in the Northeast just an indication of positivity rates just slightly increasing, enough to be concerned that this is the second wave starting that has been expected. So parts of New York City are starting to see that in the Brooklyn and Queens area, and we're going to see what that means.

We've heard from Dr. Fauci, of course, in the recent past saying, you know, the US is not in a good place right now, and we're sort of repeating that cycle as political tensions continue to weigh down any sort of national strategy. But meanwhile, hearing about, you know, the vaccine race and the focus on that, we know that Inovia, which was early on one of the prime contenders in the race, has really fallen back, delaying a Phase 2, 3 trial based on questions that need to be answered for the FDA. So waiting to hear to see what those questions look like and when they can go forward. But of course, we know there are already four contestants, if you will, in the race right now, and that continues to move forward.